Trevor Martin, Mammoth Biosciences CEO (Ore Huiying/Bloomberg via Getty Images)
April 25, 2024 07:00 AM EDT
Deals

Re­gen­eron and Mam­moth strike $100M deal to pair tiny CRISPR ed­i­tors with new de­liv­ery idea

Andrew Dunn

Senior Biopharma Correspondent

Re­gen­eron is ex­pand­ing its ge­net­ic med­i­cine ef­forts and will work with Cal­i­for­nia start­up Mam­moth Bio­sciences on gene-edit­ing pro­grams reach­ing parts of the hu­man body be­yond …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times